Anna Frömming

Anna Frömming

Company: NOXXON

Job title: Senior Scientist, Medical Science

Seminars:

Panel Discussion: Combination vs. Single Agent Therapy: What Does the Future Look Like? 4:00 pm

• Discussing the advantages and challenges of single agent vs. combination of myeloid therapies with existing treatment regimens • Highlighting areas of need in combinations based on mechanistic understanding and medical need • Considering the challenges of multi-agent therapy with toxicity and demonstrating added benefit of combination therapy to regulatorsRead more

day: Day One

Clearing Out the Myeloid Compartment to Drive Effector Cell Function, Demonstrating Clinical Mechanisms, & Benefit of Combination Therapies Targeting the CCL2 & CXCL12 Pathways 4:30 pm

• Outlining resistance mechanisms to therapies such as checkpoints and T cell therapies, and demonstrating tumor regression in resistant patients through combination therapy • Deciphering the mechanisms through which myeloid cells drive resistance to other therapies, and showing restored anti-tumor function through blocking myeloid recruitment • Deploying myeloid therapies to overcome resistance in synergy with…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.